-Alkermes Announces FDA Approval of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder

Press/Media

Period2 Jun 2021

Media coverage

1

Media coverage

  • Title-Alkermes Announces FDA Approval of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder
    Media name/outletENP Newswire
    Country/TerritoryUnited Kingdom
    Date2/06/21
    PersonsRené S. Kahn, René S. Kahn, Rene Kahn
View all 1
View less